Skip to main content
Clinical Trials/NCT02439151
NCT02439151
Completed
Not Applicable

New Lung Ventilation Strategies Guided by Transpulmonary Pressure in VV-ECMO for Severe ARDS

Rui Wang1 site in 1 country104 target enrollmentMay 1, 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Respiratory Distress Syndrome, Adult
Sponsor
Rui Wang
Enrollment
104
Locations
1
Primary Endpoint
Proportion weaned from VV-ECMO
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

Extracorporeal membrane oxygenation (ECMO) has been widely used in patients with severe acute respiratory distress syndrome (ARDS). But how to choose mechanical ventilation strategy is still not clear for severe ARDS patients supported by ECMO. Our previous work found that, compared to the traditional "lung rest" strategy, transpulmonary pressure guide new lung ventilation strategy can better maintain lung volume reduction lung collapse, atelectasis occurs. The severe ARDS patients receiving ECMO therapy were randomized divided into a new ventilation strategy group and the conventional ventilation strategy group. The new ventilation strategy is transpulmonary pressure guide ventilator setting method, and the conventional ventilation strategy is Extracorporeal Life Support Organization (ELSO) guide ventilation method. Compare the difference between the two groups of patients in lung injury, and explore the lung protection mechanism of new lung ventilation strategies guided by transpulmonary pressure. Our research group considered that transpulmonary pressure guide new lung ventilation strategy can provide more effective lung protection. And it will be further used in clinical work.

Registry
clinicaltrials.gov
Start Date
May 1, 2015
End Date
June 25, 2020
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Rui Wang
Responsible Party
Sponsor Investigator
Principal Investigator

Rui Wang

Principal Investigator

Beijing Chao Yang Hospital

Eligibility Criteria

Inclusion Criteria

  • ARDS cause reversible;
  • Pure oxygen is given, but PaO2/FiO2\<80;
  • P(A-a)O2\>600mmHg;
  • Murray score≥3.0;

Exclusion Criteria

  • peak inspiratory pressure\>30cmH2O;
  • high FiO2\>0.8;
  • ventilation\>7 days;
  • contraindication to heparinization;
  • non-reversible central nervous system injury
  • chronic disease with a short life expectancy

Outcomes

Primary Outcomes

Proportion weaned from VV-ECMO

Time Frame: After patients randomized grouping 60 days

Respiratory failure was alleviated and then ECMO withdrawal could be considered

Secondary Outcomes

  • 60-day mortality(After patients randomized grouping 60 days)

Study Sites (1)

Loading locations...

Similar Trials